Stock Analysis
MBX Biosciences, Inc. Common Stock (MBX) Stock Analysis
MBX Biosciences, Inc. Common Stock (MBX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
MBX Biosciences, Inc. Common Stock (MBX) currently has an AIQ Score of 68/100, indicating a bullish setup. Quality is the strongest factor at 74/100. Risk is the weakest current factor at 50/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
MBX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $55.94 |
| AIQ Score | 68/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $2.72B |
| P/E Ratio (TTM) | -18.28 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$1.29 |
| Revenue (Q3 FY2026) | $0 |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.26 |
| Volume | 855.45K |
| 52-week range | $23.07-$72.64 |
| RSI 14 | 53.28 |
| 50-Day SMA | $55.78 |
| 200-Day SMA | $46.32 |
| Analyst Price Target | $106.67 |
| Next Earnings | Mar 11, 2027 |
MBXMBX Biosciences, Inc. Common Stock
Healthcare / Biotechnology
Leader
Sector Leader
Latest quote
- Momentum71
- Value—
- Quality74
- Risk resilience50
- Sentiment—
MBX Stock Analysis Summary
MBX Biosciences, Inc. Common Stock (MBX) currently has an AIQ Score of 68/100, indicating a bullish setup. Quality is the strongest factor at 74/100. Risk resilience is the weakest current factor at 50/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, MBX has AIQ Score of 68/100 with Quality base of 74/100 and fading Risk resilience at 50/100. Wait for component alignment before adding exposure.
Quality (74/100) leads while Risk resilience (50/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 2.62% stock move · MBX classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is MBX Bullish or Bearish Right Now?
MBX currently has a bullish overall setup. Quality is the strongest factor at 74/100, while Risk Resilience is weakest at 50/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 74/100.
- - Momentum is constructive at 71/100.
- - Price is +0.29% above its 50-day SMA.
- - Analyst target implies +90.68% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (34 vs 4).
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
MBX's Technical Analysis Consensus is currently Strong Buy, with 34 buy, 8 neutral, and 4 sell votes. MBX's 14-day RSI is 53.28, which places the stock in a neutral momentum range. MBX's beta is 1.26, indicating greater market sensitivity than the broad market.
What Changed in MBX?
The largest recent change in MBX is Momentum moving up by 4.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the MBX Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
MBX Decision Framework
Public evidence layers, setup checks, and risk context for MBX Biosciences, Inc. Common Stock.
MBX Biosciences, Inc. Common Stock (MBX) Stock Analysis
MBX Biosciences, Inc. Common Stock has an AIQ Score of 68/100 in a Bullish regime. Quality is strongest at 74/100. Beta is 1.26, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | MBX is in a Bullish AIQ regime with score 68/100. |
| Signal Conflict | The primary conflict is that quality leads at 74/100 while risk lags at 50/100. |
| Factor Evidence | Momentum 71/100 · Quality 74/100 · Risk 50/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 74/100.
Momentum is 71/100 and RSI (14) is 53.3.
MBX is in a Bullish regime at 68/100.
Risk factor is 50/100 with beta 1.26 and annual volatility 77.34%.
Current conflict: quality leads at 74/100 while risk lags at 50/100.
MBX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
MBX Fundamentals
MBX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
MBX Technical Analysis
MBX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
MBX Stock Catalysts
Track MBX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
MBX Dividend Analysis
MBX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
MBX Financial Data
MBX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
MBX Risk Analysis
MBX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
MBX Stock News
MBX stock news, market tone, recent headlines, and catalyst context.
MBX vs Biotechnology Peers
Current peer cohort: MBX · MDGL · MIRM · MLYS · NAMS. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| MBX Current stock | 68/100 | — | 71/100 | 50/100 | 1.42 | 77.34% | Current |
| MDGL Madrigal Pharmaceuticals, Inc. | 57/100 | 66/100 | 40/100 | 63/100 | -0.32 | 42.57% | MBX vs MDGL |
| MIRM Mirum Pharmaceuticals, Inc. | 53/100 | 57/100 | 54/100 | 51/100 | 0.79 | 48.60% | MBX vs MIRM |
| MLYS Mineralys Therapeutics, Inc. | 33/100 | — | 23/100 | 35/100 | -1.48 | 61.66% | MBX vs MLYS |
| NAMS NewAmsterdam Pharma Company N.V. | 41/100 | 42/100 | 22/100 | 48/100 | -0.91 | 53.82% | MBX vs NAMS |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for MBX: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching MBX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for MBX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
MBX Stock FAQ
What is MBX stock price today?
MBX Biosciences, Inc. Common Stock's current stock price is $55.94. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is MBX bullish or bearish right now?
MBX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is MBX's market cap?
MBX's market cap is $2.72B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is MBX's current P/E ratio?
MBX's current P/E ratio is -18.28 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is MBX's RSI?
MBX's 14-day RSI is 53.28 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is MBX above its 50-day and 200-day moving averages?
MBX is 0.29% from its 50-day SMA and 20.76% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is MBX's next earnings date?
MBX's next earnings date is currently listed as Mar 11, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does MBX pay a dividend?
MBX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.